Successful Treatment of Opioid-Refractory Cancer Pain with Short-Course, Low-Dose Ketamine

Julie M. Waldfogel, Suzanne Nesbit, Steven Cohen, Sydney E Dy

Research output: Contribution to journalArticle

Abstract

Opioids remain the mainstay of treatment for severe cancer pain, but up to 20% of patients have persistent or refractory pain despite rapid and aggressive opioid titration, or develop refractory pain after long-term opioid use. In these scenarios, alternative agents and mechanisms for analgesia should be considered. This case report describes a 28-year-old man with metastatic pancreatic neuroendocrine cancer with severe, intractable pain despite high-dose opioids including methadone and a hydromorphone patient-controlled analgesia (PCA). After treatment with short-course, low-dose ketamine, his opioid requirements decreased by 99% and pain ratings by 50%, with the majority of this decrease occurring in the first 48 hours. As this patient's pain and opioid regimen escalated, he likely experienced some component of central sensitization and hyperalgesia. Administration of ketamine reduced opioid consumption by 99% and potentially “reset” neuronal hyperexcitability and reduced pain signaling, allowing for improved pain control.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalJournal of Pain and Palliative Care Pharmacotherapy
DOIs
StateAccepted/In press - Oct 17 2016

Fingerprint

Intractable Pain
Ketamine
Opioid Analgesics
Pain
Therapeutics
Hydromorphone
Central Nervous System Sensitization
Patient-Controlled Analgesia
Methadone
Hyperalgesia
Cancer Pain
Pancreatic Neoplasms
Analgesia

Keywords

  • cancer pain
  • ketamine
  • NMDA
  • opioid-refractory

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Pharmacology (medical)

Cite this

Successful Treatment of Opioid-Refractory Cancer Pain with Short-Course, Low-Dose Ketamine. / Waldfogel, Julie M.; Nesbit, Suzanne; Cohen, Steven; Dy, Sydney E.

In: Journal of Pain and Palliative Care Pharmacotherapy, 17.10.2016, p. 1-4.

Research output: Contribution to journalArticle

@article{a411ef3cc7374ef694b1e2bce72a5c9b,
title = "Successful Treatment of Opioid-Refractory Cancer Pain with Short-Course, Low-Dose Ketamine",
abstract = "Opioids remain the mainstay of treatment for severe cancer pain, but up to 20{\%} of patients have persistent or refractory pain despite rapid and aggressive opioid titration, or develop refractory pain after long-term opioid use. In these scenarios, alternative agents and mechanisms for analgesia should be considered. This case report describes a 28-year-old man with metastatic pancreatic neuroendocrine cancer with severe, intractable pain despite high-dose opioids including methadone and a hydromorphone patient-controlled analgesia (PCA). After treatment with short-course, low-dose ketamine, his opioid requirements decreased by 99{\%} and pain ratings by 50{\%}, with the majority of this decrease occurring in the first 48 hours. As this patient's pain and opioid regimen escalated, he likely experienced some component of central sensitization and hyperalgesia. Administration of ketamine reduced opioid consumption by 99{\%} and potentially “reset” neuronal hyperexcitability and reduced pain signaling, allowing for improved pain control.",
keywords = "cancer pain, ketamine, NMDA, opioid-refractory",
author = "Waldfogel, {Julie M.} and Suzanne Nesbit and Steven Cohen and Dy, {Sydney E}",
year = "2016",
month = "10",
day = "17",
doi = "10.1080/15360288.2016.1231732",
language = "English (US)",
pages = "1--4",
journal = "Journal of Pain and Palliative Care Pharmacotherapy",
issn = "1536-0288",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Successful Treatment of Opioid-Refractory Cancer Pain with Short-Course, Low-Dose Ketamine

AU - Waldfogel, Julie M.

AU - Nesbit, Suzanne

AU - Cohen, Steven

AU - Dy, Sydney E

PY - 2016/10/17

Y1 - 2016/10/17

N2 - Opioids remain the mainstay of treatment for severe cancer pain, but up to 20% of patients have persistent or refractory pain despite rapid and aggressive opioid titration, or develop refractory pain after long-term opioid use. In these scenarios, alternative agents and mechanisms for analgesia should be considered. This case report describes a 28-year-old man with metastatic pancreatic neuroendocrine cancer with severe, intractable pain despite high-dose opioids including methadone and a hydromorphone patient-controlled analgesia (PCA). After treatment with short-course, low-dose ketamine, his opioid requirements decreased by 99% and pain ratings by 50%, with the majority of this decrease occurring in the first 48 hours. As this patient's pain and opioid regimen escalated, he likely experienced some component of central sensitization and hyperalgesia. Administration of ketamine reduced opioid consumption by 99% and potentially “reset” neuronal hyperexcitability and reduced pain signaling, allowing for improved pain control.

AB - Opioids remain the mainstay of treatment for severe cancer pain, but up to 20% of patients have persistent or refractory pain despite rapid and aggressive opioid titration, or develop refractory pain after long-term opioid use. In these scenarios, alternative agents and mechanisms for analgesia should be considered. This case report describes a 28-year-old man with metastatic pancreatic neuroendocrine cancer with severe, intractable pain despite high-dose opioids including methadone and a hydromorphone patient-controlled analgesia (PCA). After treatment with short-course, low-dose ketamine, his opioid requirements decreased by 99% and pain ratings by 50%, with the majority of this decrease occurring in the first 48 hours. As this patient's pain and opioid regimen escalated, he likely experienced some component of central sensitization and hyperalgesia. Administration of ketamine reduced opioid consumption by 99% and potentially “reset” neuronal hyperexcitability and reduced pain signaling, allowing for improved pain control.

KW - cancer pain

KW - ketamine

KW - NMDA

KW - opioid-refractory

UR - http://www.scopus.com/inward/record.url?scp=84991486016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991486016&partnerID=8YFLogxK

U2 - 10.1080/15360288.2016.1231732

DO - 10.1080/15360288.2016.1231732

M3 - Article

SP - 1

EP - 4

JO - Journal of Pain and Palliative Care Pharmacotherapy

JF - Journal of Pain and Palliative Care Pharmacotherapy

SN - 1536-0288

ER -